

Virchow Biotech to produce 200 M Sputnik V doses annually

22 March 2021 | News

The technology transfer is expected to be completed in the Q2 of 2021 followed by full-scale commercial production of Sputnik V



The Russian Direct Investment Fund (RDIF) and Hyderabad based Virchow Biotech Private Limited (part of the Virchow Group), one of the leading vaccine and pharmaceutical producers in India, announce the agreement to produce in the country up to 200 million doses per year of Sputnik V, the world's first registered vaccine against coronavirus.

The technology transfer is expected to be completed in the Q2 of 2021 followed by full-scale commercial production of Sputnik V. Virchow Biotech capacities will help facilitate global supply of Sputnik V to international partners of RDIF.

Kirill Dmitriev, CEO, Russian Direct Investment Fund, commented, "Vaccine partnerships are the only way to overcome the pandemic. The world continues its fight against coronavirus and we see a growing interest in Sputnik V vaccine as it is one of the most efficient vaccines available. The agreement with Virchow Biotech is an important step to facilitate the full-scale local production of the vaccine in India and to supply our international partners globally."

Dr Tummuru Murali, Managing Director, Virchow Biotech, said, "We are glad to sign a cooperation agreement with RDIF to produce the Sputnik V coronavirus vaccine. Virchow's proven capabilities in large scale drug substance manufacturing should help meet the global demand for this vaccine. We are also happy to learn of the positive feedback that this vaccine has been receiving from all countries."